Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | MMP2 | P08253 | 4/20 | 0.70 |
| ▸ | MMP9 | P14780 | 4/20 | 0.70 |
| ▸ | MMP8 | P22894 | 4/20 | 0.70 |
| ▸ | MMP13 | P45452 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | ELANE | P08246 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563905 | 0.88 | RAB9A (0.78) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL2333007 | 0.88 | RAB9A (0.69) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL913895 | 0.82 | NPC1 (0.70) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL6565102 | 0.82 | RAB9A (0.69) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL6169453 | 0.81 | RAB9A (0.65) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL914149 | 0.81 | RAB9A (0.61) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL29576857 | 0.81 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL692792 | 0.81 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL6567424 | 0.81 | ELANE (0.62) | MEN1KMT2AMAPTRAB9ATDP1 | |
| SCHEMBL2244223 | 0.80 | MMP2 (1.00) | MEN1KMT2AMAPTRAB9AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | MEN1 1609/4885KMT2A 2584/4885MAPT 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.